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dian8.00) at baseline. Results differed according to countries, with a mean of 12.13
(SD5.17,Median11.00) in France, 9.32 (SD4.17,Median8.00) inGermany and 8.00
(SD3.89,Median7.00) inUK.About 30%of those identified at baseline still hadCDat
6, 12, 18 and 24months. Patients with CDwere found to havemore severe symptoms
(PANSS 67.7 vs. 42.5 p0.0001), a lower QoL (EQ-5D index score: 0.71 vs. 0.77 p0.001),
lower functioning (GAF: 45.9 vs. 59.0 p0.001), more severe side effects (SSES: 0.74 vs.
0.66 p0.03) and to be more depressed (CDSS: 3.09 vs. 2.55 p0.001). Results were
consistent within countries. CONCLUSIONS: Our study suggests that patients with
CD form a stable population overtime with higher clinical burden. Research on the
cognitive impairment of schizophrenia is of key importance in schizophrenia,more so
even than positive or negative symptoms.
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OBJECTIVES:Most antipsychotics were developed with the goal of addressing psy-
chopathology symptoms and maintaining the stability of patients. With the num-
ber of antipsychotics in the market, a paradigm shift instead of therapy evolution
will be the key to product success. Maintenance therapy will be inadequate and
new antipsychotics will have to demonstrate improvement in symptom remis-
sions and recovery, which can be validated by the ability to live and function
independently. The objective of this study is to evaluate similarities and differ-
ences between instruments that assess functional outcomes, to evaluate func-
tional outcome endpoints validated by newer atypicals and to understand how
these endpoints increase the value perception of a new antipsychotic.METHODS:
An online literature search was conducted to identify instruments and functional
domainsmeasured. Current atypicalswere evaluated for functional endpoint stud-
ies measured. Primary research was conducted with five payers from plans with
managed Medicaid to understand how functional outcome measures influence
their value perception. RESULTS: Twelve different instruments were cross ana-
lyzed for eighteen functional domain measurements. Our analysis show that the
most common functional domains measured are ability to form extended social
relationships (n92%), self-care (n75%), and occupational improvement (n67%)
while only two instruments measured life satisfaction, vitality, communication,
recreation, and public safety. Among the current atypicals, paliperidone included
functional outcome endpoints using the PSP scale to demonstrate efficacy. Payers
interviewed also stated that demonstrating functional improvements and ability to
translate this to daily living would be a key factor in justifying value and obtaining
favorable access for new antipsychotics. CONCLUSIONS:With a variety of instru-
ments available and the vast combination of possible functional domain endpoints
that can be measured, choosing an instrument that is objective, reliable, easily
administered and simple but comprehensive enough to measure impact in daily
function would be a powerful tool to demonstrate successful treatment.
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OBJECTIVES: Antipsychotic polypharmacy is frequently used in schizophrenia al-
though the incremental effect for relapse prevention is uncertain. The purpose of
this study is to compare risks of relapse between polypharmacy andmonotherapy
based on an observational study. Propensity score matching (PSM) and a latent
variable model (LVM) were used to correct for selection bias.METHODS: Analyses
were based on data from a multinational prospective cohort study that enrolled
1208 patients, followed over 2 years (EuroSC). The effect of treatment (combination
therapy vs. monotherapy) on the risk of relapse was estimated using Cox models.
PSMwas used to create two comparable groups of patients. Propensity scores were
derived from 11 variables measuring disease severity, quality of life, depression
and functioning at baseline. A LVMwas used to account for bias related to unmea-
sured confounding factors. It consisted of two parts estimated simultaneously: a
logisticmodel predicting treatment choice and a Coxmodel on time to relapse. The
model assumed that an unmeasured factor affecting risk of relapse was taken into
account in the choice of treatment. All analyses were performed in a Bayesian
framework, usingWinBugs. RESULTS:Matched groups each included 344 patients,
with relapse rates of 51% for monotherapy and 59% for polypharmacy. The hazard
ratio for relapse with monotherapy versus polypharmacy was 0.77 (95% CI: 0.63,
0.94) based on the simple Cox model and 1.34 (0.87, 2.39) based on LVM. The LVM
was better according to the Deviance Information Criterion. CONCLUSIONS: Re-
sults of the LVM suggest that polypharmacy is associated with a reduced risk of
relapse, and contradict results based on PSM ignoring bias related to unmeasured
confounding factors. The LVMappears to be a usefulmethod to detect unmeasured
confounding. Further research on the specification of latent variables is recom-
mended to accurately quantify treatment effects.
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OBJECTIVES: The purpose of this study is to: 1) characterize the changes in utiliza-
tion of psychotropicmedications among adults with anxiety disorder over a 6-year
period (2004-2009), and 2) identify factors associatedwith psychotropicmedication
use. METHODS: Patients with anxiety disorder were identified in the 2004 to 2009
Medical Expenditure Panel Survey (MEPS). Psychotropic medication use was ascer-
tained from a self-reported prescription file. The number and percentage of pa-
tients with anxiety using a psychotropic medication was calculated for each year
and drug class. We used t-tests to compare psychotropic medication use between
2004 and 2009, and a logistic regression model to identify the factors associated
with psychotropic medication use. RESULTS: The estimated number of adult pa-
tients who reported having an anxiety disorder increased from 18.9 million in 2004
to 21.4 million in 2009. The percentage of patients who reported ever using a psy-
chotropic medication grew from 62.5% in 2004 to 68.6% in 2009 (p0.05) and over
one-third of patients reported ever using a selective serotonin reuptake inhibitors
(SSRI) (35.3% in 2004 to 37.1% in 2009). From 2004 to 2009, there was a significant
increase in the use of benzodiazepines (26.1% to 32.9%, p0.01), serotonin-norepi-
nephrine reuptake inhibitors (SNRI) (6.5% - 10.5%, p0.01), and atypical antipsy-
chotics (4.8% to 8.4%, p0.01). A higher prevalence and significant increase in the
use of benzodiazepines was observed among older adults aged 65 years (43.9% in
2004 - 53.0% in 2009, p0.01). Multivariate logistic regression results showed that
white race, female gender, higher education, private insurance, and comorbid
mood disorders were associated with self-reported psychotropic medication use.
CONCLUSIONS: In the US, psychotropic medication use among patients with anx-
iety increased from 2004 to 2009. The high prevalence and increasing trend of
benzodiazepine use among older patients with anxiety disorder needs more re-
search to evaluate its implications.
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OBJECTIVES: Compare treatment patterns, health care resource utilization and
costs in patients with bipolar disorder newly treated with quetiapine IR (QTP-IR) or
XR (QTP-XR).METHODS: An observational, retrospective cohort study utilizing the
HealthCore Integrated Research Database identified patients (18 - 64 years) with an
ICD-9 diagnosis of bipolar disorder and 1 pharmacy claim for QTP-IR or QTP-XR
between October 2, 2008 and July 31, 2010. Outcomes included: patient character-
istics at the index date (first claim for QTP-IR/QTP-XR); 12-month pre-index clinical
characteristics, health care resource utilization and costs (inpatient, outpatient
and ER visits; pharmacy and other costs); 12-month post-index treatment patterns,
health care resource utilization and costs, assessed using generalized linear mod-
els adjusted for multiple variables. RESULTS: A total of 3049 patients with bipolar
disorder were analyzed (QTP-IR, n2,398; QTP-XR, n651). Prior to initiation of
QTP, the cohorts had some different characteristics, which were adjusted for. Pa-
tients initiating treatment with QTP-XR were more likely to have no change or
discontinuation of their index therapy (8.8% vs. 5.7%; OR 1.44 [95% CI 1.03, 2.00],
p0.05) comparedwith QTP-IR. The average daily dose (ADD;mean) of QTP-XRwas
higher than QTP-IR (225 mg/day vs 175 mg/day, p0.0001). An ADD of 300-800 mg
was reached sooner (15.6 days vs. 30.8 days, p0.01) and inmore patients (44.2% vs.
27.2%, p0.0001) initiated with QTP-XR compared with QTP-IR. There were no dif-
ferences in total healthcare costs between cohorts; however, patients initiated
with QTP-XR were less likely to be hospitalized for mental-health related reasons
(OR 0.65 [95% CI 0.50, 0.85], p0.01), and incurred lowermental-health related costs
($6686 vs. $7577, p0.01), compared with QTP-IR. CONCLUSIONS: Treatment pat-
terns and dosing differed in patients with bipolar disorder treated with QTP-XR
compared with QTP-IR in real-world practice. Mental-health related hospitaliza-
tions and costs were reduced in the 12 months following patients initiating treat-
ment with QTP-XR compared with QTP-IR.
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OBJECTIVES:AttentionDeficit/HyperactivityDisorder (ADHD) is oneof themost com-
monly diagnosed behavioral disorder among children. Main goal of the treatment of
ADHD is to reduce the symptoms of ADHD and improve physical and mental func-
tioning. Different factors affect utilization of ambulatory care by ADHD patients. Our
knowledge of these factors, however, is limited. This study tries to fill this gap. Results
from this study can help in identifying factors that might be helpful in reducing dis-
parity in ambulatory care received by ADHD patients. METHODS: This study used
data from 2003-2008 Medical Expenditure Panel Survey (MEPS). Sample consisted of
patients with ADHD who were identified using International Classification of Dis-
eases, ninth revision, Clinical Modification (ICD-9-CM) codes. Independent variables
were selected based on previous studies in the area of ambulatory visits utilization.
Negative binomial regression at a 5% significance level was conducted to estimate the
relationship betweenpatient characteristics andnumber of patient’s visit to the office
based physicians. RESULTS: Prevalence of ADHD was 1.59% (n28,355,049). Most of
the patients were male (66.57%), less than/equal to17 years old (66.14%), White
(84.16%), and had private health insurance (65%). Females had 1.28 times (Incidence
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